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Abstract: Nanoparticles are nanometer-scaled particles, and can be utilized in the form of 
nanocapsules, nanoconjugates, or nanoparticles themselves for the treatment of retinopathy, 
including angiogensis-related blindness, retinal degeneration, and uveitis. They are thought 
to improve the bioavailability in the retina and the permeability of therapeutic molecules 
across the barriers of the eye, such as the cornea, conjunctiva, and especially, blood-retinal 
barriers (BRBs). However, consisting of multiple neuronal cells, the retina can be the target 
of neuronal toxicity of nanoparticles, in common with the central and peripheral nervous 
system. Furthermore, the ability of nanoparticles to pass through the BRBs might increase the 
possibility of toxicity, simultaneously promoting distribution in the retinal layers. In this regard, 
we discussed nanotechnology and nanotoxicology in the treatment of retinopathy. 
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1. Introduction 
Nanoparticles (NPs) are small-sized particles that are nanoscale in three dimensions 
(http://www.ncbi.nlm.nih.gov/mesh/68053758). In the field of ophthalmology, NPs received attention 
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as one of the novel drug delivery systems (DDS) that overcome the barriers of the eye including cornea, 
conjunctiva, and blood-retinal barriers (BRB) [1,2]. In particular, retinopathy might be the main target 
of NP-based medicine in ophthalmology, because it is hard for specific drugs to reach the retina with 
the appropriate concentration due to restricted permeability caused by BRBs [1–3]. BRB functions as a 
selective barrier between nervous and circulatory systems [4,5], and consists of inner and outer BRBs. 
Inner BRB is the dynamic structure consisting of retinal endothelial cells, pericytes, and astrocytes, 
and outer BRB is the tight junction between retinal pigment epithelium (RPE) cells [5,6].  
We previously reported that gold NPs (AuNPs) of which sizes were 20 nm could pass through the 
BRB, whereas 100 nm GNPs were not observed in any of the retinal layers when they were 
administered intravenously [7]. These findings suggested that NPs with a small enough diameter might 
overcome limited penetration of therapeutic agents with larger sizes across the inner BRBs. Similarly, 
the periocular route is also a promising path for therapeutic NPs, because the sclera has a large surface 
area and relatively high permeability, so long as NPs could penetrate into the outer BRBs [3]. 
In this review, we discussed technological advances and toxicology issues of nanoparticles in the 
treatment of retinopathy. 
2. Retinopathy as the Target of NP-Based Medicine 
Current therapeutic attempts using various NPs in the treatment of retinopathy are summarized in 
Table 1, and clinical manifestations of representative diseases with retinopathy are presented in Figure 1. 
Table 1. Retinopathy as the target of nanoparticle-based therapeutic approach. 
Material Type  Size  (nm)  Concentration  Animal model  Administration  Reference 
Angiogenesis-related blindness 
Gold Nanoparticle  20  1  μM OIR  IVT  [8] 
Gold  Nanoparticle  50  500 nM  Cell work only  N/A  [9] 
Nanoceria  Nanoparticle  3–5  1 mM  VLDLR KO  IVT  [10] 
PLA/PLA-PEO Nanocapsule  302  0.12  mg/μL Laser  CNV  IVT  [11] 
PLGA Nanoconjugate  270–420 N/A  Laser  CNV  IV  [12] 
PLGA-chitosan Nanocapsule  260  N/A  Laser  CNV  IVT  [13] 
PLGA-chitosan Nanocapsule  260  N/A  OIR  IVT  [14] 
Silicate Nanoparticle  57 10  μg/mL OIR  IVT [15] 
Silver  Nanoparticles  50  500 nM  Cell work only  N/A  [16,17] 
Retinal degeneration 
Gelatin Nanoconjugate  585  N/A  RCS  rat  IVT  [18] 
Lipid Nanocapsule  40–200  N/A  rd10  mouse  Topical  [19] 
Nanoceria Nanoparticle −5 0.1–1  μM Light-induced  RD  IVT  [20] 
Nanoceria Nanoparticle  N/A  1  mM  tubby mouse  Intracardial  [21] 
PEG Nanoconjugate    175.9  N/A Light-induced  RD  Subretinal  [22] 
PEG Nanocapsule  −8 3.06  μg/μL rds
+/− mouse  Subretinal  [23,24] 
Uveitis 
PEG Nanocapsule  95–112  N/A  EAU  IVT  [25] 
PLA Nanocapsule  100-200  N/A  EAU  IV  [26] 
CNV: choroidal neovascularization; EAU: experimental autoimmune uveitis; IV: intravenous; IVT: 
intravitreal; KO: knockout; N/A: not applicable or not available; NP: nanoparticle; OIR: oxygen-induced 
retinopathy; PEG: poly(ethylene glycol); PEO: poly(ethylene oxide); PLA: polylactic acid; PLGA: 
polylactic-co-glycolic acid; RCS: Royal College of Surgeon; RD: retinal degeneration; VLDLR: very 
low density lipoprotein receptor. Int. J. Mol. Sci. 2011, 12  8290 
 
 
Figure 1. Clinical manifestations of representative diseases of retinopathy, as targets of 
nanoparticle-based medicine. (a) Angiogenesis-related blindness. Subretinal hemorrhage  
is observed in a patient with age-related macular degeneration (AMD), and retinal 
neovascularization is a characteristic found in patients with diabetic retinopathy (DR) and 
retinopathy of prematurity (ROP); (b) Retinal degeneration. Retinitis pigmentosa (RP) is 
characterized by diffusely degenerative retina with pigmented lesions. Stargardt disease is 
an inherited macular degeneration, and yellowish-white flecks are identified in the macula 
in this patient; (c) In the eye with uveitis, conjunctival injection (top) and keratoprecipitates 
(bottom) can be observed. 
 
2.1. Angiogenesis-Related Blindness 
Angiogenesis-related blindness (ARB) indicates the spectrum of retinal disorders of which 
pathogenesis is related with pathologic angiogenesis, including age-related macular degeneration 
(AMD), diabetic retinopathy (DR), and retinopathy of prematurity (ROP) [4]. These three diseases 
affect mostly elderly, middle-aged, and newborn patients, respectively, resulting in visual deterioration 
in corresponding age groups. Conventional treatment options for ARB were surgery and focal 
treatment, such as laser photocoagulation and cryotherapy. In recent years, intravitreal injection of 
anti-vascular endothelial growth factor (VEGF) monoclonal antibodies (mAb) has been widely 
performed to treat pathologic angiogenesis. However, despite the considerable effect of anti-VEGF 
mAb, it has limitations in that repeated injections are inevitable due to relatively short durability, and 
repeated injections up to seven or eight times a year increased injection-related complications [1,2]. Int. J. Mol. Sci. 2011, 12  8291 
 
 
Also, direct inhibition by anti-VEGF mAb is known to influence retinal neuronal cells, aggravate 
retinal ischemia, and induce mitochondrial disruption of photoreceptor cells [27–29]. 
NPs are thought to overcome the limitations of current intraocular injection of anti-VEGF mAb, 
because they can improve therapeutic efficiency by increasing bioavailability [1]. We previously reported 
that AuNPs inhibit retinal neovascularization via suppression of VEGF receptor-2 activation [8], and 
Kalishwaralal et al. also suggested inhibitory effect of AuNP on VEGF-induced angiogenesis and 
vascular permeability [9]. The exact mechanisms of antiangiogenic effect of AuNP are yet to be found, 
however, the binding capacity of AuNP to heparin-binding proteins of certain VEGF isoforms such as 
VEGF-165 was considered to be one of the possible mechanisms [30]. Interestingly, silicate NPs also 
evidenced to have an antiangiogenic effect on retinal neovascularization, suggesting shape, mass, or 
size as well as backbone materials of NP might be important factors in antiangiogenic effect of NPs [15]. 
Furthermore, silver NPs blocked VEGF-induced proliferation and migration of endothelial cells, and 
the mechanism might induce apoptosis [16,17]. Another example of NPs exerting antiangiogenic effect 
is nanoceria, cerium oxide NPs, of which injection resulted in reduction of reactive oxygen species 
(ROS) and regression of pathologic vascular lesions in Vldlr knockout mice [10]. 
As previously mentioned, NPs are also utilized as the novel DDS to deliver therapeutic agents 
to  target organs or tissues. For this purpose, polymers including polylactic acid (PLA) and   
polylactic-co-glycolic acid (PLGA) are widely used [1,31,32]. In the treatment of ARB, nanocapsules 
encapsulating integrin antagonist peptide or plasminogen kringle 5 (K5) demonstrated to inhibit 
choroidal neovascularization (CNV) in the laser-induced CNV mice models [11,13]. PLGA 
nanocapsules encapsulating K5 also ameliorates retinal neovascularization in the oxygen-induced 
retinopathy (OIR) mice model and vascular leakage in the streptozocin-induced diabetes model [14]. 
These studies showed that nanocapsules of which sizes were about 300 nm effectively deliver 
antiangiogenic molecules to the retina and even subretinal spaces where CNV occurred. 
Singh  et al. reported nanocapsules loaded with plasmid of anti-VEGF intraceptor could be 
conjugated with surface peptide and trasferrin [12]. These NPs are examples of nanoconjugates, engineered 
NPs harboring bound modules that target specific tissues and cells (http://www.ncbi.nlm.nih.gov/ 
mesh/68058726). PLGA nanocapsules with Flt23K plasmid also allowed targeted gene delivery with 
intravenous administration, and inhibited progression of pathologic angiogenesis in the laser-induced 
CNV rat model [12]. 
2.2. Retinal Degeneration 
Retinal degeneration, occurred in inherited or genetic ocular diseases such as retinitis pigmentosa 
(RP) and Stargardt disease, is also one of the targets of NP-based therapeutics in retinopathy. RP is a 
retinal degenerative disease, initially affecting the rod photoreceptor cells [33]. Stargardt disease is 
named after Karl Stargardt, who identified and described clinical features patients from two   
families [34]. From the patients with both diseases, various genetic aberrations were reported, and 
some of them have been the targets of gene therapy [35]. However, leaving the use of antioxidant aside, 
there is no definite cure for retinal degeneration, and we have much to do for stable delivery and 
application of gene therapy [33,35]. Int. J. Mol. Sci. 2011, 12  8292 
 
 
Interestingly, nanoceria prevented light-induced degeneration of photoreceptor cells by reducing 
levels of toxic ROS in the retinal cells [20]. A recent report from the same group demonstrated that 
nanoceria could extend photoreceptor cell life span in tubby mice, which exhibited progressive 
cochlear and retinal degeneration, resulting in suppression of progression of degenerative changes in 
the retina when they are injected systemically [21]. These studies suggested the possible action of 
small NPs mimicking enzymes such as superoxide dismutase and catalase. 
Solid lipid nanocapsules loaded with an inhibitor for ceramide signaling pathway lowered retinal 
ceramide levels and prevented photoreceptors from apoptotic death [19]. The more interesting part of 
this study was that NPs were administered topically, and therapeutic agents passed through corneal 
barrier, exerting actions in the retinal layers. Intravitreal injection of gelatin nanoconjugates with basic 
fibroblast growth factor also prevented photoreceptor degeneration by inhibiting apoptosis in a   
well-known animal model of retinal degeneration, the Royal College of Surgeon rat [18]. NPs 
developed by Read et al. demonstrated the features of both nanoconjugates and nanocapsules [22]. The 
poly(ethylene glycol) (PEG) NPs were conjugated with the peptide for ocular delivery (nanoconjugates), 
and contained an expression cassette for glial cell line-derived neurotrophic factor (nanocapsules). 
Furthermore, after subretinal delivery of compacted DNA into PEG NPs, gene expression was 
sustained for up to four months, and degenerative changes were retarded in the animal model of retinal 
degeneration [23,24]. 
2.3. Uveitis 
Uveitis is the inflammation of uveal tissues: the iris, ciliary body, and choroid. In some patients 
with uveitis, we could observe inflammatory cells in the anterior chamber and corneal precipitates by 
the slitlamp examination (Figure 1C). Like other organs, to prevent damage related with chronic 
inflammation, corticosteroid and other immunosuppressive therapies have been utilized in the 
treatment of uveitis [36]. Unfortunately, subconjunctival or intravitreal injection of corticosteroid   
has relatively short action, and uveitis itself has a characteristic of frequent relapse. Therefore, 
biodegradable and non-biodegradable implants of corticosteroid were developed to reduce the injection 
numbers and enable stable release of therapeutic agents [3,37,38].  
NPs also can be an answer for the treatment of uveitis with increased bioavailability and prolonged 
action. PLA NPs encapsulating betamethasone phosphate reduced clinical response and immunologic 
reaction in experimental autoimmune uveoretinitis (EAU) rats [26]. PEG-coated NPs with tamoxifen 
also showed inhibitory effect on inflammation in EAU rats [25]. Interestingly, in this study, intravitreal 
injection of free tamoxifen did not alter the course of EAU, and after the injection of PEG-coated NPs, 
NPs were distributed inside and outside of resident ocular cells, suggesting increased biodistribution 
and effectiveness of therapeutic agents with the aid of NPs. 
3. Neuronal Toxicity of NPs in Retinopathy 
Therapeutic application of NPs in retinopathy has received much attention, however, toxicity on 
neuronal cells and other resident cells in the retina should be validated before applying NPs to real 
patients. The retina is a layered structure consisting of three layers of nucleated cells and two 
plexiform layers [4]. Upon stimulation by light, responses by cone and rod photoreceptor cells are Int. J. Mol. Sci. 2011, 12  8293 
 
 
converted to electrical signals and transmitted to the optic nerve via synapses between neuronal cells 
and bipolar, horizontal, and amacrine cells [39]. If cells participating in this process are damaged or 
affected by external factors such as therapeutic agents or infectious organisms, visual response may 
deteriorate. Thus, candidate NPs should be validated not to have definite toxic effect on the retina in in 
vitro and in vivo assays before clinical application. 
3.1. Studies on Nanotoxicology in Retinopathy 
In retinopathy, most studies on nanotoxicology have been performed as a part of studies on the 
therapeutic effect of NPs, and reports focusing solely on the toxic effect of NPs are limited. However, 
previously mentioned studies on application of NPs in retinopathy mostly have confirmed no evidence 
of definite toxicity on the retina at the therapeutic dosage by histologic examination, and sometimes 
electroretinography, which measured electrical response of the retina.  
Bourges et al. reported the distribution of PLA NPs within the intraocular tissues and their potential 
to release encapsulated material [40]. The administered concentration was 2.2 mg/mL, and the 
intensity of inflammation in the retinal layers was increased 6 to 24 hours, however, decreased 
markedly by 48 hours. Interestingly, NPs were remnant within the RPE cells four months after the 
intravitreal injection without definite histologic change in the retinal layers. This study demonstrated 
that PLA NPs, widely used nanocapsules, might be utilized with expectation of sustained delivery of 
therapeutic agents. Merodio et al. also reported prolonged residence of NPs in the vitreous cavity  
two weeks after a single intravitreal injection [41]. Toxicity was examined with the histologic 
evaluation and immunohistochemisty of ocular autoantigens, arrestin and rhodopsin. Bovine serum 
albumin NPs, of about 300 nm and a concentration was 200 mg/mL, did neither induce inflammatory 
reaction in the retinal tissue nor alter the organization of the retinal layers and expression of 
retinal autoantigens. 
There have been studies evaluating the toxicity according to different types, concentrations, and the 
polymer tail lengths of NPs [42–45]. In a rabbit model, intravitreal AuNPs at concentrations of   
67 μmol/0.1 mL and 670 μmol/0.1 mL did not induce retinal or optic nerve toxicity after 1 week and  
1 month, examined by histologic examination via the light microscope [42]. As for PEG-compacted 
DNA NPs utilized for the treatment of retinal degeneration, subretinal injection of NPs at concentrations 
of 0.3, 1.0, and 3.0 μg/μL did neither induce infiltration of polymorphonuclear neutrophils or 
lymphocytes nor increase the markers for inflammatory cells [43]. Hafeli et al. reported that iron 
magnetic NPs coated with the shortest polyehylenoxide tails were more toxic than NPs with longer 
tails [44]. Interestingly, alteration of surface characteristics of NPs resulted in decreased toxicity on 
endothelial and RPE cells. Prow et al. demonstrated safety and effectiveness of magnetic NPs by 
comparison with chitosan and poly{[(cholesteryl oxocarbonylamido ethyl) methyl bis(ethylene) 
ammonium iodide] ethyl phosphate} NPs [45]. In this study, the authors evaluated eyes grossly for 
RPE abnormalities, retinal degeneration, and inflammation, and concluded that intravitreal and 
subretinal injection of magnetic NPs were nontoxic to the retina. Int. J. Mol. Sci. 2011, 12  8294 
 
 
3.2. Possible Mechanisms of Neuronal Toxicity Induced by NPs  
Possible mechanisms of neuronal toxicity of NPs were postulated by various studies. ROS is one of 
the most widely suggested mechanisms of neurotoxicity of NPs [46–49]. Titanium dioxide (TiO2) NPs 
induced intracellular formation of ROS in neuronal and glial cells, resulting in disturbance of the 
electrical activity of neuronal networks [46,47]. In a gene expression study regarding oxidative stress 
and antioxidant, silver NPs caused alteration of gene expression pattern in the tissues from the caudate 
nucleus, frontal cortex, and hippocampus of mice [48,49]. Manganese and copper NPs induced 
differential expression of genes regarding dopamine synthesis and metabolism [49]. These data 
suggested that enzymatic alterations might affect toxicity in dopamine-producing neuronal cells. 
Besides neuronal cells, microglial cells were reported to be cells most likely to respond to NPs [50,51]. 
When treated with silica NPs, microglial cells took up NPs as they engulf foreign materials in 
phagocytosis, increasing the production of intracellular ROS and reactive nitrogen species [50]. In 
addition, silicate NPs altered cytokine release of microglial cells, suggesting the possibility of affecting 
surrounding neuronal cells. AuNPs also demonstrated to up-regulate toll-like receptor 2, interlukin  
1-alpha, granulocyte macrophage colony-stimulating factor and nitric oxide in microglial cells [51]. 
Increase in intracellular calcium was observed in the well-differentiated neuronal cell line when 
they were treated with silica NPs at a concentration that was toxic [52]. These results showed that the 
effect of NPs on neuronal cell survival might be related to the degree of perturbation of calcium 
homeostasis. In primary murine cortical networks on neurochips, carbon black, iron, titanium dioxide 
NPs induced changes of the electrical activity [46]. Liu et al. reported that the change of action 
potential properties was related with depression of voltage-gated sodium current by silver NPs [53]. In 
hippocampal neurons, silver NPs of 10 μg/mL decreased peak amplitude and overshoot of the evoked 
single action potential. 
3.3. Factors Affecting Neuronal Toxicity of NPs  
Among the factors that are likely to affect neuronal toxicity of NPs, size and concentration are 
thought to be the most important ones. In the studies on microglial reponse, 200 nm silica NPs did not 
show any toxic effect even at relatively high concentrations (292 μg/mL), whereas 50 nm-sized NPs 
decreased neuronal survival in a dose-dependent way [52]. As for copper NPs, 40 nm-sized NPs 
exerted the maximum toxic effect when compared with 60 and 80 nm-sized NPs [54]. These   
data might result from the fact that smaller NPs have more surface molecules per particle available, 
thereby interacting with surrounding cells or proteins more efficiently [55]. Furthermore, smaller 
AuNPs (10 nm) demonstrated to be widely distributed in various organ systems including blood, liver, 
spleen, kidney, testis, thymus, heart, and brain, whereas larger NPs (50, 100, and 250 nm) were 
detected only in blood, liver, spleen when they were injected intravenously in rats [56]. We also 
showed that intravenously administered 20 nm-sized AuNPs were observed in all retinal layers 
including neuronal, endothelial, and peri-endothelial glial cells, however 100 nm-sized AuNPs were 
not detected in the retina [7]. In this regard, smaller NPs have higher surface molecules and improved 
penetration into target organs, simultaneously increasing the possibility of toxicity in neuronal cells. 
However, using 10, 30, 60, and 200 nm sized zinc NPs, Deng et al. demonstrated that Zinc NPs Int. J. Mol. Sci. 2011, 12  8295 
 
 
manifested no size-dependent toxic effect on neuronal stem cells, only evidencing dose-dependent 
toxicity [57]. Dose and concentration effect was definitely observed in various studies [46,52–54,57]. 
As with therapeutic agents with larger scales, NPs should be administered at a proper concentration to 
induce aimed effects, not toxic effects. Furthermore, although no definite subacute physiological 
damage was found, the accumulation of AuNPs in the brain and other organs was increased depending 
on the doses administered in mice [58].  
Time might be another important factor in neuronal toxicity. To demonstrate time-dependent 
dislocation and potential damage of titanium dioxide NPs on central nervous system, female mice  
were intranasally instilled with NPs every other day. As expected, the group with 30 day-exposure 
demonstrated significantly increased oxidative damage expressed as lipid peroxidation [59]. Surface 
charge of NPs also affected toxicity and integrity of the blood-neural barrier [60,61]. In cellular 
viability, hemolysis, and bacterial viability assays, anionic AuNPs demonstrated less toxicity than 
cationic ones [60]. Furthermore, in the evaluation of effect of neutral, anionic, and cationic NPs on 
blood-brain barrier (BBB), neutral and low concentrations of anionic NPs had no effect on BBB 
integrity, however, cationic NPs and high concentrations of anionic NPs exerted alteration in BBB [61]. 
In this regard, authors suggested neutral or low concentrations of anionic NPs could be utilized as DDS 
for therapeutic agents targeted to brain.  
There was also a concern that materials constituted of NPs had an influence on neuronal   
toxicity [46,57]. Gramowski et al. reported that titanium dioxide NPs caused oxidation damage in 
neuronal and glial cells, however, exposure to carbon black and iron NPs at relatively higher 
concentrations did not induce significant formation of intracellular ROS [46]. Zinc oxide NPs 
demonstrated only dose-dependent, but no size-dependent toxic effects on neural stem cells [57]. 
These results might support the concept that zinc or zinc ion itself induced the toxicity, because toxic 
effects were observed regardless of size of NPs. 
Factors affecting toxicity of NPs on neuronal cells are summarized in Figure 2. 
Figure 2. Characteristics of NPs affecting neuronal toxicity. 
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4. NPs on Blood-Retinal Barrier: Increasing the Bioavailability versus Affecting the BRB 
We previously reported the ability of 20 nm sized AuNPs to pass through BRB [7], and NPs of 
similar sizes were known to cross BBB [44]. These characteristics may help to increase the bioavailability 
of therapeutic agents for diseases of the retina and the brain. However, at the same time, increased 
biodistribution in the retina and the brain can cause more toxicity. Therefore, researchers and clinicians 
who want to use NPs as therapeutic agents should carefully determine the size and concentration of 
NPs to effectively increase bioavailability and minimize possible toxicities. 
Although the inhibitory effect of AuNPs on vascular permeability in retinal endothelial cells might 
be induced by suppression of VEGF receptor or direct inhibition of specific isoforms of VEGF, this 
effect demonstrated the possible action of NPs on the restoration of diseased BRB [9]. On the contrary, 
there was a report showing the disturbance of the integrity of BBB caused by emulsifying wax   
NPs [61]. NPs of small sizes could pass through the blood neural barriers, but the effect of NPs on the 
barriers might be different according to the types or concentrations of NPs. In this regard, the 
possibility of unwanted effects on BRB should be considered in the development of therapeutic 
modalities using NPs. 
5. Nanotechnology and Nanotoxicology in Retinopathy: Friends or Foes? 
In general, there has been a growing concern that nanotechnology outgrows nanotoxicology in 
neuronal diseases. AuNPs and silicate NPs are known to be less toxic than NPs of other materials, 
however, the exact toxicity profiles of those NPs are yet to be presented, and there is also a possibility 
that neuronal toxicities of NPs can be different according to small differences in the production 
procedure or characteristics of NPs, even though the backbone materials are the same. As previously 
mentioned, size, dose, dosing time, surface charge, and other factors can attribute differences in 
neuronal toxicities of NPs. 
Magnetic NPs could be protected from acidic erosion when coated with amorphous silica, 
stabilizing the NPs and reducing toxicities in in vitro cellular toxicity assays [62]. According to the 
charges of side chains, the same NPs exerted different toxicities in various cell types [60]. Smaller NPs 
could penetrate the various barriers including BBB and BRB [45,53], and with these NPs, we could 
administer lesser concentrations to the patients. With current technology regarding production of NPs, 
we can change these characteristics of NPs, minimizing neuronal toxicities. 
Some authors suggested plausible recommendations for studies on NPs with regard to concerns on 
nanotoxicology [55]. The properties of NPs should be characterized sufficiently before studies with 
those NPs are performed. The parameters include chemical composition, size (with distribution), 
surface characteristics, presence of coating, degree of aggregation, water solubility, and zeta potential. 
These guidelines support the notion that certain characteristics of NPs might influence toxicities, and 
consideration of those properties might improve methods to lessen toxicity and activate discussion 
about possible modification to improve toxicity profiles of NPs. Progressive nanotechnology brought 
about the issue of nanotoxicology, however, the answer for reducing toxicity of NPs will be from 
advances in nanotechnology. Int. J. Mol. Sci. 2011, 12  8297 
 
 
6. Future Directions 
In this review, we discussed presumptive applications and possible toxicities of NPs in retinopathy. 
Conventional treatment options for retinopathy, include surgery, focal treatment, and intravitreal anti-
VEGF mAb, and have considerable therapeutic effects on patients with ARB, retinal degeneration, and 
uveitis. However, NPs still have possibilities for wide application in retinopathy, because NPs can pass 
through BRB or other barriers in the eye, and prolonged residence of NPs in the eye can reduce 
treatment numbers, which is one of the most bothersome problems of intravitreal anti-VEGF mAb. In 
considering characteristics of NPs that affect neuronal toxicities and BRB, researchers should focus on 
the development of NPs with enhanced efficacy and minimal toxicity. Current technology regarding 
the production of NPs can help increase efficacy with modification of surface charge or conjugated 
molecules, and cautiousness concerning possible toxicities of NPs on the retina and even the nervous 
system, will reduce toxicities. As nanotechnology progresses, we look forward to the development of 
“safe, but effective” NP technology in retinopathy, which will help patients who have suffered from 
catastrophic visual loss. 
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